Business News
Financial news, mergers and acquisitions, partnerships, and alliances.
Merck Buys Exclusive Rights to Develop Hengrui Pharma's Lp(a) Inhibitor Outside of China
Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.
Verve Therapeutics to Kick off Base-Editing Cardiovascular Drug Phase I Trial in the US
The firm's Heart-2 study of VERVE-102, which is designed to inactivate the PCSK9 gene, is already underway in Canada and the UK.
Angle Hoping to Continue Developing Parsortix HER2 CTC Assay With BlissBio, Eisai
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
Alnylam's RNAi TTR Silencing Drug Amvuttra FDA Approved for Transthyretin Amyloidosis Cardiomyopathy
The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.
In Brief This Week: 4baseCare, Flatiron Health, Primo Partners, Circular Genomics
News items for the week of March 17, 2025.